Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Gaucher Disease Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Gaucher Disease Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Replace Enzymes
1.3.3 Glucosylceramide Synthase Inhibitors
1.3.4 Osteoporosis Drugs
1.4 Market Segment by Application
1.4.1 Global Gaucher Disease Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Type I Gaucher Disease
1.4.3 Type II Gaucher Disease
1.4.4 Type III Gaucher Disease
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Gaucher Disease Drugs Revenue (2015-2026)
2.1.1 Global Gaucher Disease Drugs Revenue (2015-2026)
2.1.2 Global Gaucher Disease Drugs Sales (2015-2026)
2.2 Gaucher Disease Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Gaucher Disease Drugs Sales by Regions (2015-2020)
2.2.2 Global Gaucher Disease Drugs Revenue by Regions (2015-2020)
2.3 Global Top Gaucher Disease Drugs Regions (Countries) Ranking by Market Size
2.4 Gaucher Disease Drugs Industry Trends
2.4.1 Gaucher Disease Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Gaucher Disease Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Gaucher Disease Drugs Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Gaucher Disease Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Gaucher Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Gaucher Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Gaucher Disease Drugs Sales in 2019
3.2 Global Top Manufacturers Gaucher Disease Drugs by Revenue
3.2.1 Global Gaucher Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Gaucher Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Gaucher Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gaucher Disease Drugs as of 2019)
3.4 Global Gaucher Disease Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Gaucher Disease Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Gaucher Disease Drugs Market
3.7 Key Manufacturers Gaucher Disease Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Gaucher Disease Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Gaucher Disease Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Gaucher Disease Drugs Price by Type (2015-2020)
4.1 Global Gaucher Disease Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Gaucher Disease Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Gaucher Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Gaucher Disease Drugs Price Forecast by Type (2021-2026)
5 Global Gaucher Disease Drugs Market Size by Application
5.1 Global Gaucher Disease Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Gaucher Disease Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Gaucher Disease Drugs Price by Application (2015-2020)
5.2 Global Gaucher Disease Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Gaucher Disease Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Gaucher Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Gaucher Disease Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Gaucher Disease Drugs Breakdown Data by Company
6.2 North America Gaucher Disease Drugs Breakdown Data by Type
6.3 North America Gaucher Disease Drugs Breakdown Data by Application
6.4 North America Gaucher Disease Drugs Breakdown Data by Countries
6.4.1 North America Gaucher Disease Drugs Sales by Countries
6.4.2 North America Gaucher Disease Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Gaucher Disease Drugs Breakdown Data by Company
7.2 Europe Gaucher Disease Drugs Breakdown Data by Type
7.3 Europe Gaucher Disease Drugs Breakdown Data by Application
7.4 Europe Gaucher Disease Drugs Breakdown Data by Countries
7.4.1 Europe Gaucher Disease Drugs Sales by Countries
7.4.2 Europe Gaucher Disease Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Gaucher Disease Drugs Breakdown Data by Company
8.2 Asia Pacific Gaucher Disease Drugs Breakdown Data by Type
8.3 Asia Pacific Gaucher Disease Drugs Breakdown Data by Application
8.4 Asia Pacific Gaucher Disease Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Gaucher Disease Drugs Sales by Regions
8.4.2 Asia Pacific Gaucher Disease Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Gaucher Disease Drugs Breakdown Data by Company
9.2 Latin America Gaucher Disease Drugs Breakdown Data by Type
9.3 Latin America Gaucher Disease Drugs Breakdown Data by Application
9.4 Latin America Gaucher Disease Drugs Breakdown Data by Countries
9.4.1 Latin America Gaucher Disease Drugs Sales by Countries
9.4.2 Latin America Gaucher Disease Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Type
10.2 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Application
10.3 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Gaucher Disease Drugs Sales by Countries
10.3.2 Middle East and Africa Gaucher Disease Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Dong-A-Socio Holdings
11.1.1 Dong-A-Socio Holdings Corporation Information
11.1.2 Dong-A-Socio Holdings Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Dong-A-Socio Holdings Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Dong-A-Socio Holdings Gaucher Disease Drugs Products and Services
11.1.5 Dong-A-Socio Holdings SWOT Analysis
11.1.6 Dong-A-Socio Holdings Recent Developments
11.2 Genzyme Corporation
11.2.1 Genzyme Corporation Corporation Information
11.2.2 Genzyme Corporation Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Genzyme Corporation Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Genzyme Corporation Gaucher Disease Drugs Products and Services
11.2.5 Genzyme Corporation SWOT Analysis
11.2.6 Genzyme Corporation Recent Developments
11.3 ExSAR Corporation
11.3.1 ExSAR Corporation Corporation Information
11.3.2 ExSAR Corporation Business Overview and Total Revenue (2019 VS 2018)
11.3.3 ExSAR Corporation Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 ExSAR Corporation Gaucher Disease Drugs Products and Services
11.3.5 ExSAR Corporation SWOT Analysis
11.3.6 ExSAR Corporation Recent Developments
11.4 Neuraltus Pharmaceuticals
11.4.1 Neuraltus Pharmaceuticals Corporation Information
11.4.2 Neuraltus Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Neuraltus Pharmaceuticals Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Neuraltus Pharmaceuticals Gaucher Disease Drugs Products and Services
11.4.5 Neuraltus Pharmaceuticals SWOT Analysis
11.4.6 Neuraltus Pharmaceuticals Recent Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Corporation Information
11.5.2 Amicus Therapeutics Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Amicus Therapeutics Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Amicus Therapeutics Gaucher Disease Drugs Products and Services
11.5.5 Amicus Therapeutics SWOT Analysis
11.5.6 Amicus Therapeutics Recent Developments
11.6 JCR Pharmaceuticals
11.6.1 JCR Pharmaceuticals Corporation Information
11.6.2 JCR Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.6.3 JCR Pharmaceuticals Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 JCR Pharmaceuticals Gaucher Disease Drugs Products and Services
11.6.5 JCR Pharmaceuticals SWOT Analysis
11.6.6 JCR Pharmaceuticals Recent Developments
11.7 Lixte Biotechnology Holdings
11.7.1 Lixte Biotechnology Holdings Corporation Information
11.7.2 Lixte Biotechnology Holdings Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Lixte Biotechnology Holdings Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Lixte Biotechnology Holdings Gaucher Disease Drugs Products and Services
11.7.5 Lixte Biotechnology Holdings SWOT Analysis
11.7.6 Lixte Biotechnology Holdings Recent Developments
11.8 Protalix BioTherapeutics
11.8.1 Protalix BioTherapeutics Corporation Information
11.8.2 Protalix BioTherapeutics Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Protalix BioTherapeutics Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Protalix BioTherapeutics Gaucher Disease Drugs Products and Services
11.8.5 Protalix BioTherapeutics SWOT Analysis
11.8.6 Protalix BioTherapeutics Recent Developments
11.9 Greenovation Biotech
11.9.1 Greenovation Biotech Corporation Information
11.9.2 Greenovation Biotech Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Greenovation Biotech Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Greenovation Biotech Gaucher Disease Drugs Products and Services
11.9.5 Greenovation Biotech SWOT Analysis
11.9.6 Greenovation Biotech Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Gaucher Disease Drugs Sales Channels
12.2.2 Gaucher Disease Drugs Distributors
12.3 Gaucher Disease Drugs Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Gaucher Disease Drugs Sales Forecast (2021-2026)
13.1.1 Global Gaucher Disease Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Gaucher Disease Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Gaucher Disease Drugs Sales Forecast (2021-2026)
13.2.2 North America Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.2.3 North America Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Gaucher Disease Drugs Sales Forecast (2021-2026)
13.3.2 Europe Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Gaucher Disease Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Gaucher Disease Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Gaucher Disease Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Gaucher Disease Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Gaucher Disease Drugs Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Dong-A-Socio Holdings、Genzyme Corporation、ExSAR Corporation、Neuraltus Pharmaceuticals、Amicus Therapeutics、JCR Pharmaceuticals、Lixte Biotechnology Holdings、Protalix BioTherapeutics、Greenovation Biotech
【免責事項】
https://www.globalresearch.jp/disclaimer